124 results
Page 3 of 7
8-K
EX-99.1
hga8joiefj n57wmxq
4 Nov 19
Karyopharm Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress
7:07am
8-K
EX-99.1
eggkkvxq cer9qbi
16 Sep 19
Entry into a Material Definitive Agreement
7:09am
8-K
EX-99.1
wm6tn1 0kmnub99gul3e
6 Aug 19
Results of Operations and Financial Condition
7:13am
8-K
EX-99.1
cfkbuhg6qjeju0ve9aq
3 Jul 19
Karyopharm Announces FDA Approval of XPOVIOTM(selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
1:10pm
8-K
EX-99.1
yjuk0nxbdl6rv9v0ql
19 Jun 19
Karyopharm Reports Updated Data from the Phase 2b SADAL Study at the 2019 International Conference on Malignant Lymphoma
4:05pm
8-K
EX-99.1
hy617b hygm2
14 Jun 19
Other Events
7:33am
424B5
85znudtwd lsptu
10 May 19
Prospectus supplement for primary offering
4:16pm
8-K
EX-99.1
gl2hv5 b4jia
9 May 19
Results of Operations and Financial Condition
7:10am
PRE 14A
900d7p55kp78jh0ta6
2 Apr 19
Preliminary proxy
4:29pm
8-K
EX-99.1
ruhdx8ecrfvrjp422
15 Mar 19
Karyopharm Announces FDA Extension of Review Period for Selinexor New Drug Application
7:00am
POS AM
6xe63xw5kfwr
28 Feb 19
Prospectus update (post-effective amendment)
4:54pm
POSASR
whgjkie70lefx1t lgq
28 Feb 19
Automatic shelf registration (post-effective amendment)
4:17pm
8-K
EX-99.1
v1o8wmma8
28 Feb 19
Karyopharm Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
7:22am
8-K
9eqi0s1 by
25 Feb 19
Departure of Directors or Certain Officers
5:01pm